iX Biopharma Ltd. (SG:42C) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
iX Biopharma Ltd is capitalizing on the surging demand for GLP-1 drugs used in diabetes and obesity treatment with their novel sublingual semaglutide wafer, iXB 401, while leveraging their newly developed WaferlogiX technology. The company has also regained control over the licensing of Wafermine, a product for pain and depression, and is focusing on the commercialization and expansion of their anti-aging Healthspan product line, which includes sublingual NAD+ and Glutathione wafers.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.
